Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.62 |
| ▸ | CA6 | P23280 | 5/20 | 0.62 |
| ▸ | CA7 | P43166 | 5/20 | 0.62 |
| ▸ | CA9 | Q16790 | 5/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.62 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.62 |
| ▸ | CA2 | P00918 | 4/20 | 0.62 |
| ▸ | CA4 | P22748 | 4/20 | 0.62 |
| ▸ | CA5A | P35218 | 4/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.62 |
| ▸ | F13A1 | P00488 | 2/20 | 0.62 |
| ▸ | THPO | P40225 | 2/20 | 0.62 |
| ▸ | CASP2 | P42575 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | RECQL | P46063 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | CA3 | P07451 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL756934 | 0.98 | CA12 (0.59) | CA12CA6CA7CA9CA14 | |
| SCHEMBL861203 | 0.95 | CA12 (0.55) | CA12CA6CA7CA9CA14 | |
| SCHEMBL10110868 | 0.93 | CA12 (0.56) | CA12CA6CA7CA9CA14 | |
| SCHEMBL861102 | 0.93 | CASP2 (0.59) | CA12CA6CA7CA9CA14 | |
| SCHEMBL18827192 | 0.91 | CASP2 (0.62) | CA12CA6CA7CA9CA14 | |
| SCHEMBL989774 | 0.90 | — | — | |
| SCHEMBL21214219 | 0.88 | CA12 (0.60) | CA12CA6CA7CA9CA14 | |
| SCHEMBL10247635 | 0.87 | CA12 (0.46) | CA12CA6CA7CA9CA14 | |
| SCHEMBL21800043 | 0.85 | CA12 (0.43) | CA12CA6CA7CA9CA14 | |
| SCHEMBL21800028 | 0.85 | CA12 (0.43) | CA12CA6CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9333232-B2 | Methods for treating papilloma virus infection | NANOVIR LLC (US) | 2016-05-10 | — | — | US | disclosed |
| US-9333232-B2 | Methods for treating papilloma virus infection | NANOVIR LLC (US) | 2016-05-10 | — | — | US | disclosed |
| US-9290551-B2 | Compounds for treating papilloma virus infection | NANOVIR LLC (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150239943-A1 | COMPOUNDS FOR TREATING PAPILLOMA VIRUS INFECTION | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2015-08-27 | — | — | US | disclosed |
| US-8993609-B2 | Compounds for treating papilloma virus infection | NANOVIR, LLC (US) | 2015-03-31 | — | — | US | disclosed |
| US-20120225809-A1 | COMPOUNDS FOR TREATING PAPILLOMA VIRUS INFECTION | NANOVIR, LLC (US) | 2012-09-06 | — | — | US | disclosed |
| US-8119677-B2 | Polyamides containing amino butyric acid-based building blocks | NANOVIR, LLC (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100015084-A1 | Compounds for Treating Papilloma Virus Infection | NANOVIR, LLC (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090306164-A1 | Methods for Treating Papilloma Virus Infection | NANOVIR, LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-7589171-B2 | Polyamides for treating human papilloma virus | NANOVIR, LLC (US) | 2009-09-15 | — | — | US | disclosed |
| US-20070293417-A1 | Polyamides for treating human papilloma virus | NANOVIR, LLC | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225809-A1 | COMPOUNDS FOR TREATING PAPILLOMA VIRUS INFECTION | POLI, TLR3, PMAIP1 | CA12 168/4885CA6 633/4885CA7 299/4885 |
| US-20090306164-A1 | Methods for Treating Papilloma Virus Infection | POLI, VHL, TLR3 | CA12 45/4885CA6 392/4885CA7 125/4885 |
| US-20150239943-A1 | COMPOUNDS FOR TREATING PAPILLOMA VIRUS INFECTION | POLI, TLR3, PMAIP1 | CA12 168/4885CA6 633/4885CA7 299/4885 |
| US-20100015084-A1 | Compounds for Treating Papilloma Virus Infection | POLI, PMAIP1, TLR3 | CA12 285/4885CA6 911/4885CA7 392/4885 |
| US-20070293417-A1 | Polyamides for treating human papilloma virus | POLI, PARG, PARN | CA12 332/4885CA6 1131/4885CA7 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.